Literature DB >> 18949648

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.

Borwin Bandelow1, Joseph Zohar, Eric Hollander, Siegfried Kasper, Hans-Jürgen Möller, Joseph Zohar, Eric Hollander, Siegfried Kasper, Hans-Jürgen Möller, Borwin Bandelow1, Christer Allgulander, José Ayuso-Gutierrez, David S Baldwin, Robertas Buenvicius, Giovanni Cassano, Naomi Fineberg, Loes Gabriels, Ian Hindmarch, Hisanobu Kaiya, Donald F Klein, Malcolm Lader, Yves Lecrubier, Jean-Pierre Lépine, Michael R Liebowitz, Juan José Lopez-Ibor, Donatella Marazziti, Euripedes C Miguel, Kang Seob Oh, Maurice Preter, Rainer Rupprecht, Mitsumoto Sato, Vladan Starcevic, Dan J Stein, Michael van Ameringen, Johann Vega.   

Abstract

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

Entities:  

Mesh:

Year:  2008        PMID: 18949648     DOI: 10.1080/15622970802465807

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  153 in total

1.  How close is evidence to truth in evidence-based treatment of mental disorders?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-22       Impact factor: 5.270

Review 2.  A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.

Authors:  Dan J Stein; Nastassja Koen; Naomi Fineberg; Leonardo F Fontenelle; Hisato Matsunaga; David Osser; H Blair Simpson
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

Review 3.  Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder.

Authors:  Thomas Dresler; Anne Guhn; Sara V Tupak; Ann-Christine Ehlis; Martin J Herrmann; Andreas J Fallgatter; Jürgen Deckert; Katharina Domschke
Journal:  J Neural Transm (Vienna)       Date:  2012-06-13       Impact factor: 3.575

4.  A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder.

Authors:  Dan J Stein; David S Baldwin; Borwin Bandelow; Carlos Blanco; Leonardo F Fontenelle; Sing Lee; Hisato Matsunaga; David Osser; Murray B Stein; Michael van Ameringen
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

5.  Determinants of the severity of comorbid migraine in multiple sclerosis.

Authors:  Veronica Villani; Laura De Giglio; Giuliano Sette; Carlo Pozzilli; Marco Salvetti; Luca Prosperini
Journal:  Neurol Sci       Date:  2012-05-27       Impact factor: 3.307

6.  Topiramate augmentation in a patient with obsessive-compulsive disorder.

Authors:  Michael Van Ameringen; Beth Patterson
Journal:  J Psychiatry Neurosci       Date:  2015-09       Impact factor: 6.186

Review 7.  Can Long-Term Pharmacotherapy Prevent Relapses in Generalized Anxiety Disorder? A Systematic Review.

Authors:  Marina Dyskant Mochcovitch; Rafael Christophe da Rocha Freire; Rafael Ferreira Garcia; Antonio Egidio Nardi
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

Review 8.  Obsessive-compulsive disorder.

Authors:  Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson
Journal:  Nat Rev Dis Primers       Date:  2019-08-01       Impact factor: 52.329

9.  Long-term antidepressant use: a qualitative study on perspectives of patients and GPs in primary care.

Authors:  Renske C Bosman; Klaas M Huijbregts; Peter Fm Verhaak; Henricus G Ruhé; Harm Wj van Marwijk; Anton Jlm van Balkom; Neeltje M Batelaan
Journal:  Br J Gen Pract       Date:  2016-08-15       Impact factor: 5.386

10.  Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.

Authors:  Stefano Pallanti; Silvia Bernardi; Sarah Antonini; Nikhilesh Singh; Eric Hollander
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.